WHO requests complete data on trials of Oxford coronavirus vaccine
The World Health Organization (WHO) hopes to publish complete data on trials of the AZD1222 coronavirus vaccine being developed by the British-Swedish company AstraZeneca and the University of Oxford. On Saturday, November 28, RIA Novosti reports.
“We've heard from AstraZeneca that they want to conduct a full trial of small doses of the vaccine to better understand the higher efficacy of small doses. This will be welcomed as the current trials are examining the full dose, ”the WHO said, noting that only by examining the details, they can better understand the effectiveness of the vaccine.
The organization stressed that the information published by the developers in a recent press release is not enough, and it is too early to comment on them.
On November 23, the developers of the AZD1222 vaccine said it showed an average efficacy of 70 percent. During the tests, two variants of drug administration were tested. In the first case, more than 2.7 thousand people AZD1222 were injected first in a half dose, and a month later in full, and the effectiveness was 90 percent. The variant with the introduction of two full doses with a difference of a month was tested on 9 thousand people, and the result was only 62 percent.
